Technical Analysis for VIRX - Viracta Therapeutics, Inc.
Grade | Last Price | % Change | Price Change |
---|---|---|---|
F | 0.83 | -2.21% | -0.02 |
VIRX closed down 2.21 percent on Friday, April 26, 2024, on 29 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions.
Earnings due: May 6
*** please verify all earnings dates ***ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Weak or Absent | Down | Down | Down |
Date | Alert Name | Type | % Chg |
---|---|---|---|
NR7 | Range Contraction | 0.00% | |
NR7-2 | Range Contraction | 0.00% | |
Narrow Range Bar | Range Contraction | 0.00% | |
Inside Day | Range Contraction | 0.00% | |
Wide Bands | Range Expansion | 0.00% | |
NR7 | Range Contraction | -2.21% | |
Narrow Range Bar | Range Contraction | -2.21% | |
Wide Bands | Range Expansion | -2.21% | |
200 DMA Resistance | Bearish | -0.96% | |
Inside Day | Range Contraction | -0.96% |
Alert | Time |
---|---|
Possible NR7 | about 5 hours ago |
Possible Inside Day | about 5 hours ago |
10 DMA Resistance | about 10 hours ago |
Down 2 % | about 10 hours ago |
Down 1% | about 10 hours ago |
Free Daily (Stock) Chart Reading
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 05/06/2024
Viracta Therapeutics, Inc., a precision oncology company, engages in developing drugs for the treatment of virus-associated malignancies. It is developing nanatinostat, an oral combination therapy in combination with the antiviral agent valganciclovir that is in Phase II clinical trial for Epstein-Barr virus-positive lymphoma. The company was founded in 2007 and is headquartered in Cardiff, California.
Sector: Healthcare
Industry: Biotechnology
Keywords: Cancer Lymphoma Hematology Antiviral Drug Anatomical Pathology
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Cancer Lymphoma Hematology Antiviral Drug Anatomical Pathology
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 2.38 |
52 Week Low | 0.43 |
Average Volume | 124,934 |
200-Day Moving Average | 0.89 |
50-Day Moving Average | 0.92 |
20-Day Moving Average | 0.97 |
10-Day Moving Average | 0.84 |
Average True Range | 0.12 |
RSI (14) | 43.18 |
ADX | 20.53 |
+DI | 18.62 |
-DI | 24.42 |
Chandelier Exit (Long, 3 ATRs) | 0.97 |
Chandelier Exit (Short, 3 ATRs) | 1.02 |
Upper Bollinger Bands | 1.24 |
Lower Bollinger Band | 0.70 |
Percent B (%b) | 0.24 |
BandWidth | 56.17 |
MACD Line | -0.04 |
MACD Signal Line | -0.01 |
MACD Histogram | -0.0241 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 0.87 | ||||
Resistance 3 (R3) | 0.87 | 0.86 | 0.86 | ||
Resistance 2 (R2) | 0.86 | 0.85 | 0.86 | 0.86 | |
Resistance 1 (R1) | 0.84 | 0.84 | 0.84 | 0.84 | 0.86 |
Pivot Point | 0.83 | 0.83 | 0.83 | 0.83 | 0.83 |
Support 1 (S1) | 0.82 | 0.82 | 0.81 | 0.82 | 0.80 |
Support 2 (S2) | 0.81 | 0.82 | 0.81 | 0.80 | |
Support 3 (S3) | 0.79 | 0.81 | 0.80 | ||
Support 4 (S4) | 0.79 |